Biothera has announced that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms. AS1402 is a monoclonal antibody that targets an aberrant form of the cell-surface protein MUC1 that is widely expressed in many types of cancer. Prior to the acquisition, the experimental drug had been in Phase 2 development. Biothera plans to study the combination therapy of Imprime PGG and AS1402 in future cancer trials. The indication has yet to be determined.
Top Posts
- MedImmune and NGM Biopharmaceuticals sign diabetes collaboration agreement
- MedImmune files Synagis suit against Abbott
- Allergan buys rights to Serenity Pharma’s Ser-120
- Alliance failure rates, revisited
- Novartis to close NeuTec Pharma
- Evotec expands its collaboration with MedImmune
- Amicus Therapeutics and GlaxoSmithKline Fabry trial fails to hit primary endpoints
- Immune Design signs licensing deal with MedImmune
- GSK buys stake in JCR Pharmaceuticals
- Aridis acquires mAb portfolio from Kenta Biotech
Inside Silico
Archives
- June 2013 (27)
- May 2013 (37)
- April 2013 (34)
- March 2013 (34)
- February 2013 (41)
- January 2013 (35)
- December 2012 (40)
- November 2012 (34)
- October 2012 (56)
- September 2012 (41)
- August 2012 (35)
- July 2012 (48)
- June 2012 (40)
- May 2012 (44)
- April 2012 (39)
- March 2012 (63)
- February 2012 (50)
- January 2012 (91)
- December 2011 (96)
- November 2011 (91)
- October 2011 (88)
- September 2011 (99)
- August 2011 (56)
- July 2011 (96)
- June 2011 (105)
- May 2011 (100)
- April 2011 (106)
- March 2011 (115)
- February 2011 (102)
- January 2011 (110)
- December 2010 (107)
- November 2010 (106)
- October 2010 (122)
- September 2010 (119)
- August 2010 (55)
- July 2010 (99)
- June 2010 (106)
- May 2010 (92)
- April 2010 (113)
- March 2010 (116)
- February 2010 (110)
- January 2010 (113)
- December 2009 (82)
- November 2009 (74)
- October 2009 (104)
- September 2009 (77)
- August 2009 (34)
- July 2009 (80)
- June 2009 (62)
- May 2009 (68)
- April 2009 (25)
- March 2009 (61)
- February 2009 (10)
- January 2009 (4)
- December 2008 (2)
- November 2008 (3)
- September 2008 (2)
- April 2008 (3)
- February 2008 (1)
- January 2008 (1)
- November 2007 (4)
- October 2007 (7)
- September 2007 (5)
- August 2007 (2)
- July 2007 (21)
Blogroll
- Avelient BioPharm Blog
- Biotech Blog
- Biotech News
- Bnet Health Care
- Bnet Pharma
- Drug Discovery Today
- FDA News
- FierceBiotech
- Health Economics Blog
- I Am Biotech
- James Hatton
- LifeSciences World
- MarketWatch
- MaRS Blog
- Medical News Today
- OnBioVC
- OneMedPlace
- Orange Book Blog
- Patent Docs
- Pathophilia
- Pharma Marketing Blog
- Pharma’s Cutting Edge
- Pharmaceutical Executive Magazine
- PR Newswire: Biotechnology
- PR Newswire: Medical/Pharmaceuticals
- The Antibody Blog
- The Biotech Weblog
- The Health Economics Blog
- The IN VIVO Blog
- The Pink Sheet Daily
- The RPM Report
- WSJ.com: Health Blog
Research
Social networks
Silico Research · Cutting edge research about partnering and alliances
